RA CAPITAL MANAGEMENT, L.P. - 05 Jan 2026 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
CLYM
Transactions as of
05 Jan 2026
Net transactions value
+$24,888
Form type
4
Filing time
07 Jan 2026, 16:55:47 UTC
Previous filing
19 Dec 2025
Next filing
09 Jan 2026

Reporting Owners (7)

Name Relationship Address Signature Signature date CIK
RA CAPITAL MANAGEMENT, L.P. Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P. 07 Jan 2026 0001346824
RA Capital Healthcare Fund LP Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC the General Partner of RA Capital Healthcare Fund, L.P. 07 Jan 2026 0001315082
RA Capital Nexus Fund, L.P. Director 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund GP, LLC, the General Partner of RA Capital Nexus Fund, L.P. 07 Jan 2026 0001780117
RA Capital Nexus Fund II, L.P. Director 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC, the General Partner of RA Capital Nexus Fund II, L.P. 07 Jan 2026 0001825376
RA Capital Nexus Fund III, L.P. Director, 10%+ Owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund III GP, LLC, the General Partner of RA Capital Nexus Fund III, L.P. 07 Jan 2026 0001883840
Kolchinsky Peter Director, 10%+ Owner C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Peter Kolchinsky, individually 07 Jan 2026 0001384859
Shah Rajeev M. Director, 10%+ Owner C/O RA CAPITAL MANAGEMENT, L.P., 200 BERKELEY STREET, 18TH FLOOR, BOSTON /s/ Rajeev Shah, individually 07 Jan 2026 0001619841

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Purchase $24,888 +7,111 +0.21% $3.50 3,403,429 05 Jan 2026 See footnotes F1, F2, F3
holding CLYM Common Stock 2,479,872 05 Jan 2026 See footnotes F3, F4
holding CLYM Common Stock 1,226,497 05 Jan 2026 See footnotes F3, F5
holding CLYM Common Stock 483,679 05 Jan 2026 See footnotes F3, F6
holding CLYM Common Stock 2,866,375 05 Jan 2026 See footnotes F3, F7
holding CLYM Common Stock 841,087 05 Jan 2026 See footnotes F3, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.495 to $3.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
F4 These securities are held directly by Sera.
F5 These securities are held directly by the Nexus Fund.
F6 These securities are held directly by the Nexus Fund II.
F7 These securities are held directly by Nexus Fund III.
F8 These securities are held directly by the Account.

Remarks:

Dr. Andrew Levin, a Partner and Managing Director of the Adviser, serves on the Issuer's board of directors.